{
    "clinical_study": {
        "@rank": "83816", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the safety and efficacy of Avastin\n      (bevacizumab) in patients with metastatic colorectal cancer. Data will be collected from\n      patients receiving Avastin in combination with chemotherapy according to registered\n      indication in routine clinical practice."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Metastatic colorectal cancer\n\n          -  Prescribed to receive Avastin according to registered indication\n\n        Exclusion Criteria:\n\n          -  Patients not eligible for Avastin treatment according to the Summary of Product\n             Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic colorectal cancer initiated on Avastin in combination with\n        chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "191", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697449", 
            "org_study_id": "ML21889"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kragujevac", 
                        "country": "Serbia", 
                        "zip": "34000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "NIS", 
                        "country": "Serbia", 
                        "zip": "18000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sremska Kamenica", 
                        "country": "Serbia", 
                        "zip": "21204"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Serbia"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Serbia: Medicines and Medical Devices Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 4.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697449"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate (including rate of primary unresectable patients reaching stage of resectability)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}